

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
- FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers - Trump imposes up to 100% tariff on some brand name pharmaceutical companies
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era











